Follow us...

 

Search News Archives

 

Special Offers and Promotions

 

 

News Channels

 

Laboratory Products

 

 

View Channel

News

 

 

View Channel

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Brochures & Literature

 

 

View Channel

 

Conferences | Events

Proximagen Licenses Cresset’s Computational Tools for scaffold Identification and Bioisostere Replacement

publication date: Dec 5, 2014
 | 
author/source: Cresset BioMolecular Discovery Ltd

Cresset, innovative provider of computational chemistry software and services, is pleased to announce that Proximagen, a company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS), has licensed Cresset’s Forge and Spark software.

cresset logoThese applications provide extensive capabilities in SAR analysis, ligand-based molecular design and bioisosteric replacement.

"Proximagen has successfully used Cresset’s computational chemistry tools in the past to generate pharmacophores from known ligands and to identify novel chemical series by scaffold hopping,” says Dr Ed Savory, Deputy Head of Chemistry at Proximagen. “We will be using Spark to identify new drug scaffolds and to make bioisosteric core replacements. Both Spark and Forge are now important and valuable components of our drug discovery program."

“We are delighted that Proximagen have chosen to further the collaboration with Cresset, says Dr David Bardsley, Cresset’s Commercial Director. “Cresset’s continual striving for outstanding science delivered in usable software is translating into valuable results for our customers.”

About Cresset

Cresset’s software and consulting services are used by chemists from the world’s leading research organizations. Our patented methods deliver novel, realistic results for discovering, designing and optimizing the best small molecules in industry sectors including: agrochemicals, fine chemicals, flavour, fragrance, petrochemicals and pharmaceuticals. www.cresset-group.com

About Proximagen

Proximagen is a UK-based biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and is owned by Upsher-Smith Laboratories, Inc., a Minnesota-based growing pharmaceutical company.

Upsher-Smith Laboratories, Inc. founded in 1919, is a growing pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy. Improving LifeTM. With capabilities ranging from early-stage research to delivering on-market products, Upsher-Smith is committed to developing quality products that enable people to live life to its greatest potential.


more about cresset


more news from cresset




 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners